Abstract
Compounds that act as agonists for Toll-like receptors (TLRs) are considered promising candidates for drug development against cancer, including bladder cancer non-muscle invasive (BCNMI). In this context, the alternative treatments that reduce rates of recurrence, progression, and its impact on clinical outcomes of patients with BCNMI the combination of immunotherapy with P-MAP and inhib…